Sodium bicarbonate - Placebo to match ly3502970

DRUG2 trials

Sponsors

Eli Lilly & Co.

Conditions

ObesityOverweightOverweight or ObesityType 2 Diabetes

Phase 3

J2A-MC-GZGP A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

Active, not recruitingCTIS2022-502839-19-00

Eli Lilly & Co.Obesity, Overweight, Overweight or Obesity

Start: 2023-09-14Target: 516Updated: 2025-12-01

J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

CompletedCTIS2022-502837-24-00

Eli Lilly & Co.Obesity, Overweight, Type 2 Diabetes

Start: 2023-09-25End: 2025-08-07Target: 390Updated: 2025-08-12